Biocon opens up world class medical devices facility in Bengaluru
Giving out their best as a commitment to ‘Make in India for the World’ which is also well aligned with the Government’s ‘Make in India’ vision, Biocon, India’s largest and fully-integrated, innovation-led biopharmaceutical company has come up with the state-of-the-art new devices facility for manufacturing new generation, patient-friendly devices for its insulin portfolio in Bengaluru. The facility, along with Basalog One, a high-end, ready-to-use insulin glargine disposable pen for better blood sugar management for people with diabetes was inaugurated by Mr. Amitabh Kant, Secretary, Department of Industrial Promotion and Policy, Govt. of India along with Mr. Kaushik Mukherjee, Chief Secretary, Government of Karnataka and Ms. V. Manjula, Secretary, IT,BT and S&T, Government of Karnataka.
Biocon has taken the lead to take this mission forward in the area of pharmaceutical and biomedical devices and invested significantly in the facility that will provide direct and indirect employment to several hundred people. The facility will enable Biocon to leverage the country’s manufacturing expertise to develop world-class delivery devices for people with diabetes in India and other parts of the world.
Biocon’s Basalog One, a long acting basal insulin glargine presented as an innovative, pre-filled pen, is the first product to roll out of this facility. Basalog One as a ‘once a day’ product is convenient to administer and almost painless, which will enable better patient compliance and help patients manage their blood sugar levels most effectively. The pen is light weight, easy to carry and disposable.
Speaking at the launch, Mr. Amitabh Kant, Secretary, Department of Industrial Policy and Promotion, Govt of India, said, “I want to congratulate Biocon on the inauguration of this new facility and the launch of Basalog One. This product, made in such a top class facility, will make a radical difference in the lives of many millions of diabetes patients globally. It’s a huge step forward for such a product to be ‘Made in India’. I am proud of the Biocon team for the focus they have exhibited in making this dream a success.”
Ms Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon, said: “Our aim is to provide insulin products to at least one in five insulin-dependent diabetes patients, anywhere in the world. This new devices facility is a key milestone in our journey towards that goal. It will enable us to not only fulfil our commitment to ‘Make in India for the World’ but also deliver on the promise of ‘Affordable Access to Healthcare for All’. Through our product Basalog One™, we will be providing a high –end patient friendly basal insulin glargine pen in India first and global markets, subsequently.”
Biocon has collaborated with Becton Dickinson and Co. (BD), a leading global medical devices company based in the US, to specially customize the design of this device to enable it to deliver Biocon’s range of insulin products. Biocon’s Basalog One is a first-of-its-kind, disposable insulin glargine pen, designed internationally and built locally for the global markets.